Hypocholesterolemic properties of grapefruit (Citrus paradisii) and shaddock (Citrus maxima) juices and inhibition of angiotensin-1-converting enzyme activity

Journal of Food and Drug Analysis

Volumn 22, Issue 4, 2014, Pages 477-484

  Oboh, Ganiyu ^a   Bello, Fatai O ^a   Ademosun, Ayokunle O ^a  

^a FEDERAL UNIVERSITY OF TECHNOLOGY   (Nigeria)

Author keywords

Angiotensin I converting enzyme; Grapefruit; Hypocholesterolemia; Shaddock

Indexed keywords

CITRUS; CITRUS MAXIMA; CITRUS X PARADISI;

EID: 84916932222     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2014.06.005     Document Type: Article

References (29)

1. World Health Organization Global status report on noncommunicable diseases 2010 2011 WHO Geneva
2. World Health Organization Global atlas on cardiovascular disease prevention and control 2011 WHO Geneva
3. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 2006 e442
4. G. De Backer, E. Ambrosioni, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 24 2003 1601 1610
5. M.A. Austin, M.H. Carolyn, and R.L. Zimmern Familial hypercholesterolemia and coronary heart disease: A HuGE association review Am J Epidemiol 160 2004 421 429
6. S.S. Lim, T. Vos, and A.D. Flaxman A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2224 2260
7. D.J. Mabberley A classification for edible Citrus (Rutaceae) Telopea 7 1997 167 172
8. J.B. Harborne The flavonoids: Advances in research since 1986 1994 Chapman & Hall New York
9. R.M. Horowitz, and B. Gentili Flavonoid constituents of citrus S. Nagy, P.E. Shaw, M.K. Veldhuis, Citrus science and technology 1977 Avi Publishing Westport (CT) 397 426
10. K.R. Acharya, E.D. Sturrock, and J.F. Riordan ACE revisited: A new target for structure-based drug design Nature Rev Drug Discov 2 2003 891 902
11. V.L. Singleton, R. Orthofor, and R.M. Lamuela-Raventos Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteau reagent Methods Enzymol 299 1999 152 178
12. A. Meda, C.E. Lamien, and M. Romito Determination of the total phenolic, flavonoid and proline contents in Burkina Faso honey, as well as their radical scavenging activity Food Chem 91 2005 571 577
13. D.W. Cushman, and H.S. Cheung Spectrophotometric assay and properties of the angiotensin I-converting enzyme of rabbit lung Biochem Pharmacol 20 1971 1637 1648
14. N.W. Tietz Fundamentals of clinical chemistry 1982 W.B. Saunders Philadelphia 562 698
15. M.F. Lopes-Virella, P. Stone, and S. Ellis Cholesterol determination in high-density lipoproteins separated by three different methods Clin Chem 23 1977 882 884
16. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
17. E.M. Kurowska, J.D. Spence, J. Jordan, S. Wetmore, D.J. Freeman, L.A. Piche, and P. Serratore HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia AM J CLin Nutr. 72 50 2000 1095 1100
18. J.R. Sowers, and E.D. Frolich Insulin and insulin resistance: impact on blood pressure and cardiovascular disease Med Clin North Am 88 2004 63 82
19. A.J. Turner, and N.M. Hooper The angiotensin-converting enzyme gene family: Genomics and pharmacology Trends Pharmacol Sci 23 2002 177 183
20. M.F. Montenegro, L.R. Pessa, and J.E. Tanus-Santos Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin Eur J Pharmacol 607 2009 173 177
21. Y. Lin, M.A. Vermeer, and W. Bos Molecular structures of citrus flavonoids determine their effects on lipid metabolism in HepG2 cells by primarily suppressing ApoB secretion J Agric Food Chem 59 2011 4496 4503
22. A. Mohammadi, J. Macri, and R. Newton Effect of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells Arterioscler Thromb Vasc Biol 18 1998 783 793
23. R.J. Havel Triglyceride-rich lipoproteins and atherosclerosis: New perspectives Am J Clin Nutr 59 1994 795 799
24. S. Gorinstein, H. Leontowicz, and M. Leontowicz Changes in plasma lipid and antioxidant activity in rats as a result of naringin and red grapefruit supplementation J Agric Food Chem 53 2005 3223 3228
25. E.J. Schaefer, J.R. McNamara, and T. Tayler Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects Am J Cardiol 90 2002 689 696
26. J.J. Genest, J.R. McNamara, and D.N. Salem Prevalence of risk factors in men with premature coronary heart disease Am J Cardiol 67 1991 1185 1189
27. M. Amemiya-Kudo, H. Shimano, and A.H. Hasty Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes J Lipid Res 43 2002 1220 1235
28. N.M. Borradaile, L.E. de Dreu, and P.H.R. Barrett Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation Biochemistry 42 2003 1283 1291
29. B. Morin, L.A. Nichols, and K.M. Zalasky The citrus flavonoids hesperetin and nobiletin differentially regulate low density lipoprotein receptor gene transcription in HepG2 liver cells J Nutr 138 2008 1274 1281